A variety of inherited and acquired human diseases affecting the hematopoietic stem cell (HSC) can potentially be treated with genetic manipulation of the patients' HSCs. Potential applications of this technology include therapeutic approaches for common blood disorders (e.g. thalassemia), malignancies (e.g. leukemia) and infectious diseases of the blood cells, such as HIV-1 infection/AIDS. However, with a few exceptions, gene transfer into HSCs of large animal models and humans has thus far proven to be difficult and inefficient. By improving our knowledge of the biological characteristics of the human HSC we will likely gain important insights that will allow us to improve the efficiency of gene transfer in and correction of this elusive target cell. Under this project we have established in vitro and in vivo animal models of human hematopoiesis using hematopoietic progenitors obtained from cord blood, bone marrow or peripheral blood of volunteer donors. These cells are cultured in vitro in a variety of cytokines and growth factors to identify conditions that allow their survival in the absence of differentiation. The cells are then subjected to gene transfer using viral vectors that allow for integration of the transferred gene and allowed to differentiate into mature cell lineages in vitro (methylcellulose progenitor colonies) or in vivo using mouse or sheep animal models. The pattern of integration sites is studied to verify if trends indicating preferential genomic locations can be identified. These experiments allow comparison of cells with putative hematopoietic stem cell activity isolated from various sources (e.g. cord blood vs. bone marrow vs. peripheral blood) and testing of vectors and gene transfer conditions that efficiently target these cells.

Agency
National Institute of Health (NIH)
Institute
National Human Genome Research Institute (NHGRI)
Type
Intramural Research (Z01)
Project #
1Z01HG000121-06
Application #
6830361
Study Section
(GMBB)
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
2003
Total Cost
Indirect Cost
Name
Human Genome Research
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Yokoyama, Tadafumi; Yoshizaki, Ayumi; Simon, Karen L et al. (2015) Age-Dependent Defects of Regulatory B Cells in Wiskott-Aldrich Syndrome Gene Knockout Mice. PLoS One 10:e0139729
Uchiyama, Toru; Adriani, Marsilio; Jagadeesh, G Jayashree et al. (2012) Foamy Virus Vector-mediated Gene Correction of a Mouse Model of Wiskott-Aldrich Syndrome. Mol Ther :
Bosticardo, Marita; Ghosh, Amrita; Du, Yang et al. (2009) Self-inactivating retroviral vector-mediated gene transfer induces oncogene activation and immortalization of primary murine bone marrow cells. Mol Ther 17:1910-8
Sokolic, Robert; Kesserwan, Chimene; Candotti, Fabio (2008) Recent advances in gene therapy for severe congenital immunodeficiency diseases. Curr Opin Hematol 15:375-80
Muul, Linda Mesler; Candotti, Fabio (2007) Immune responses to gene-modified T cells. Curr Gene Ther 7:361-8
Sakamoto, Norihisa; Tsuji, Kazuhide; Muul, Linda M et al. (2007) Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans. Blood 110:501-8
Thrasher, Adrian J; Gaspar, H Bobby; Baum, Christopher et al. (2006) Gene therapy: X-SCID transgene leukaemogenicity. Nature 443:E5-6; discussion E6-7
Xu, Lai; Tsuji, Kazuhide; Mostowski, Howard et al. (2004) A convenient method for positive selection of retroviral producing cells generating vectors devoid of selectable markers. J Virol Methods 118:61-7
Bosticardo, Marita; Witte, Iren; Fieschi, Claire et al. (2004) Retroviral-mediated gene transfer restores IL-12 and IL-23 signaling pathways in T cells from IL-12 receptor beta1-deficient patients. Mol Ther 9:895-901
Bailo, Marco; Soncini, Maddalena; Vertua, Elsa et al. (2004) Engraftment potential of human amnion and chorion cells derived from term placenta. Transplantation 78:1439-48

Showing the most recent 10 out of 22 publications